CHICAGO, May 29, 2020 (GLOBE NEWSWIRE) -- Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, has reached a milestone ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new initiative with Bristol Myers Squibb (NYSE: BMY). This collaboration ...
CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced Tempus+, a proprietary program that powers collaborative precision oncology research ...
Tempus AI Inc. TEM announced a new collaboration initiative with Bristol Myers Squibb Co. BMY aimed at improving clinical ...
CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of Tempus N+, a program that aims to power precision medicine solutions through ...
Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced that its CARE Program (Comprehensive, Assessment, Risk, and ...
The initiative will apply its massive, multimodal dataset to build models that aim to improve diagnostic, prognostic, and predictive modeling CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (TEM), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results